Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avacopan in ANCA-Associated Vasculitis
NCT02994927Phase 3Completed
- Sponsor
- Amgen
- Start
- Mar 2017
- Primary completion
- Sep 2019
- Modality
- Small Molecules
- Countries
- 20
01
Overview
A Phase 3 trial of avacopan in Antineutrophil cytoplasmic antibody-associated vasculitis (AAV), sponsored by Amgen. Started Mar 2017; status: completed.
02
Drugs
avacopan
03
Conditions
Antineutrophil cytoplasmic antibody-associated vasculitis (AAV)
Beyond the preview
Go deeper on NCT02994927.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02994927.